Dysregulation of the PI3K/AKT/mTOR pathway is among the most frequent molecular alterations in breast cancer and plays a central role in resistance to both endocrine therapy and CDK4/6 inhibition [148]. This evidence concerns the gene CDK4 and breast cancer.